# US Gangrene Market > US Gangrene Market Research Report By Type (Dry Gangrene, Wet Gangrene, Gas Gangrene) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.8% - **2024:** $ 0.32 Million - **2025:** $ 0.34 Million - **2035:** $ 0.59 Million - **Key Players:** Smith & Nephew (GB), MediWound Ltd. (IL), Acelity L.P. Inc. (US), Organogenesis Inc. (US), Mölnlycke Health Care AB (SE), ConvaTec Group PLC (GB), B. Braun Melsungen AG (DE), 3M Company (US) **Report ID:** MRFR/Pharma/18394-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-gangrene-market-19941 --- ## Market Summary ## **US Gangrene Market Overview** As per MRFR analysis, the US Gangrene Market Size was estimated at 318.5 (USD Million) in 2023. The US Gangrene Market Industry is expected to grow from 350(USD Million) in 2024 to 770 (USD Million) by 2035. The US Gangrene Market CAGR (growth rate) is expected to be around 7.431% during the forecast period (2025 - 2035). ### **Key US Gangrene Market Trends Highlighted** The US Gangrene Market is currently witnessing several significant trends shaped by advancements in medical technology, changing patient demographics, and an increased focus on infection control. One key market driver is the rising incidence of chronic conditions, such as diabetes, which is leading to a higher occurrence of gangrene cases among patients. With an aging population and increasing prevalence rates of obesity and diabetes in the US, healthcare providers are under pressure to effectively manage and treat such cases. This growing patient pool, coupled with the rising awareness of gangrene, drives the demand for effective medical treatments and surgical procedures. Opportunities are emerging in telemedicine and home healthcare services, which provide potential market players with avenues to reach patients more effectively. As the healthcare system evolves towards more accessible and patient-centric approaches, telehealth solutions can facilitate remote monitoring and early intervention in individuals at risk of developing gangrene. Moreover, innovations in wound care treatments and regenerative medicine present new prospects for addressing complications arising from gangrene, an area where research and development investments could yield significant benefits. Recent trends also reveal a shift towards advanced therapies and personalized treatment plans, supported by growing health awareness campaigns and educational initiatives highlighting the risks of untreated wounds and infections. This trend is further supported by government efforts to improve healthcare access and quality, emphasizing the need for proactive disease management. Furthermore, collaboration between governmental health agencies and private sector organizations is on the rise, aiming to bolster research initiatives and create a better understanding of gangrene through data sharing and community outreach. Overall, these trends indicate a promising dynamic in the US Gangrene Market as it adapts to meet the evolving needs of patients and healthcare providers. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Gangrene Market Drivers** ### **Increasing Incidence of Diabetes and Obesity** The rising prevalence of diabetes and obesity in the United States is a significant driver for the US [Gangrene Market](../../../reports/gangrene-market-1875) Industry. According to the Centers for Disease Control and Prevention (CDC), as of 2020, over 34 million Americans, or approximately 10.5% of the population, have diabetes. This condition often leads to poor blood circulation and increases the risk of gangrene, particularly in diabetic foot ulcers. Furthermore, the CDC reported that approximately 42.4% of adults in the US were classified as obese in 2017-2018, which significantly heightens the risk factors associated with gangrene. Major healthcare organizations like the American Diabetes Association (ADA) actively work towards increasing awareness and management of diabetes, which indirectly influences the growth of the gangrene market, as managing these conditions remains a priority to mitigate complications such as gangrene. ### **Advancements in Surgical and Wound Care Technologies** Recent advancements in surgical techniques and wound care products bolster the US Gangrene Market Industry by improving patient outcomes and recovery times. Innovations such as skin grafting, negative pressure wound therapy, and advanced antimicrobial dressings are becoming standard practices in treating gangrene-related conditions. A report by the American College of Surgeons indicates that the adoption of minimally invasive surgical techniques has increased by nearly 20% in the last five years. These advancements not only enhance treatment efficacy but also lead to a reduction in hospital stay duration, thereby promoting market growth as facilities invest in these technologies to improve patient care. ### **Increase in Aged Population Prone to Ischemic Diseases** The aging population in the United States significantly contributes to the growth of the US Gangrene Market Industry. According to the Administration for Community Living, by 2030, one in five Americans will be over the age of 65, a demographic known to be more vulnerable to ischemic diseases, which can lead to gangrene. As older adults often present with multiple comorbidities including vascular diseases and diabetes, they require more comprehensive care. The aging trend implies a higher demand for medical interventions, contributing to increased healthcare spending and development of treatments focused on gangrene management. ## **US Gangrene Market Segment Insights** ### **Gangrene Market Type Insights** The US Gangrene Market is characterized by a varied segmentation based on Type, which includes significant categories such as Dry Gangrene, Wet Gangrene, and Gas Gangrene. Each of these types presents unique challenges and treatment requirements, indicating the complexity of managing gangrene cases. Dry Gangrene occurs when blood flow to a particular area is obstructed, leading to tissue death. This type is often associated with conditions like diabetes or atherosclerosis, making it crucial for early detection and effective management to prevent further complications in patients. Wet Gangrene, on the other hand, is typically due to bacterial infection that causes rapid tissue decay and can result from untreated wounds or severe burns, presenting urgent public health challenges. Its rapid progression underscores the need for prompt medical intervention, often requiring advanced treatment strategies to mitigate infection spread and tissue loss. Lastly, Gas Gangrene is characterized by the production of gas within tissues due to clostridial bacteria; this type can manifest suddenly and is often life-threatening. The severity and rapid onset of Gas Gangrene emphasize the importance of immediate medical response and advanced surgical options, highlighting the critical nature of awareness and education in primary care settings. Collectively, these distinct types contribute to the broader understanding of the US Gangrene Market dynamics, shaping treatment paradigms and influencing healthcare resource allocation in the United States. The complexity and varied nature of these gangrene types present both challenges and opportunities for healthcare professionals, as they adapt to evolving market trends and implement effective treatment pathways. Understanding these types is essential for improving patient outcomes, enhancing the quality of care, and driving advancements in Research and Development within the US healthcare system. These characteristics contribute to the market's growth trajectory, presenting avenues for innovation and improvement in patient care strategies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Gangrene Market Key Players and Competitive Insights** The competitive insights of the US Gangrene Market show a landscape characterized by several prominent players driving innovation and market growth. The competition within this sector is shaped by the increasing prevalence of gangrene and the rising demand for effective treatment options. Various companies are investing in research and development to enhance their portfolios, seeking to introduce new therapies that address different types of gangrene, including wet, dry, and gas gangrene. The regulatory environment in the US further influences market dynamics as firms strive to comply with strict standards while developing products that are both effective and safe for patients. The competitive advantage often hinges upon the ability to offer innovative therapies, coupled with strong marketing strategies and strategic collaborations. Merck and Co stands out in the US Gangrene Market due to its robust pipeline and established presence in the pharmaceutical landscape. The company is recognized for its commitment to developing cutting-edge therapeutic solutions, which allows it to cater effectively to the needs of healthcare professionals and patients affected by gangrene. Leveraging its extensive research capabilities and a strong distribution network, Merck and Co has positioned itself to capitalize on the growing demand for advanced treatment options. The company's strengths lie in its continuous investment in clinical trials and research initiatives aimed at improving patient outcomes, ultimately enhancing its competitive position in the market. Bristol Myers Squibb also plays a significant role in the US Gangrene Market, focusing on delivering innovative products and services that effectively address the challenges associated with gangrene treatment. The company boasts a diversified portfolio with key products that include therapies specifically developed for infection management, which is critical in gangrene cases. Bristol Myers Squibb has made notable strides in expanding its market presence through strategic mergers and acquisitions, facilitating access to advanced research capabilities and therapeutic innovations. The company’s strengths are highlighted by its agile response to market needs and its ability to leverage collaborations to enhance its offerings, thus solidifying its position in the competitive landscape of the US Gangrene Market. ### **Key Companies in the US Gangrene Market Include** - Merck and Co - Bristol Myers Squibb - AstraZeneca - Novartis - Gilead Sciences - Eli Lilly and Company - Regeneron Pharmaceuticals - Pfizer - Amgen - AbbVie - **[Biogen](https://www.biogen.com/medicines.html)** - Roche - Sanofi - Johnson and Johnson ## **US Gangrene Market Industry Developments** Recent developments in the US Gangrene Market have highlighted significant advancements in treatment options and research initiatives. Companies such as Merck and Co., Bristol Myers Squibb, and Gilead Sciences have been focusing on new therapeutic compounds targeting gangrene-related conditions. In terms of mergers and acquisitions, notable activity includes Novartis acquiring a promising biotechnology firm in September 2023, which is expected to enhance its portfolio in the treatment of chronic wounds associated with gangrene. Additionally, Pfizer has expanded its research partnerships to explore innovative therapies that reduce gangrene incidence. Market valuation has seen growth due to increasing investments in biotechnology and novel drug development, with Eli Lilly and Company and Amgen reporting substantial quarterly earnings attributed to their advancements in wound care therapies. Over the last few years, there has been a heightened emphasis on antibiotic resistance, with Roche and Sanofi launching collaborative efforts aimed at overcoming resistant infections related to gangrene in April 2022. These activities have collectively contributed to an evolving landscape in the US Gangrene Market, bolstered by increasing healthcare expenditures and a focus on advanced treatment methodologies. ## **US Gangrene Market Segmentation Insights** ### **Gangrene Market Type Outlook** - Dry Gangrene - Wet Gangrene - Gas Gangrene ## Market Drivers ### Growing Aging Population The increasing aging population in the US appears to be a significant driver for the gangrene market. As individuals age, they often experience a decline in overall health, leading to a higher incidence of chronic conditions such as diabetes and peripheral artery disease, which are known risk factors for gangrene. According to recent statistics, approximately 20% of the US population will be over 65 years old by 2030, suggesting a potential rise in gangrene cases. This demographic shift necessitates enhanced healthcare services and treatment options, thereby expanding the gangrene market. Furthermore, the aging population may require more advanced wound care solutions, which could lead to increased demand for specialized products and services within the gangrene market. ### Rising Healthcare Expenditure The escalating healthcare expenditure in the US is likely to influence the gangrene market positively. With healthcare spending projected to reach $6 trillion by 2027, there is a growing emphasis on improving treatment options and patient care. This financial commitment may lead to increased funding for research and development in the field of gangrene treatment, including innovative therapies and advanced wound care products. Additionally, higher healthcare spending could facilitate better access to medical services for patients suffering from gangrene, thereby potentially reducing the incidence of severe cases. As a result, the gangrene market may experience growth driven by enhanced treatment modalities and improved patient outcomes. ### Increased Awareness and Education There appears to be a growing awareness and education regarding gangrene and its associated risks among healthcare professionals and the general public. Campaigns aimed at educating individuals about the symptoms and prevention of gangrene are likely to lead to earlier diagnosis and treatment. This heightened awareness may result in a decrease in severe cases, thereby impacting the gangrene market positively. Furthermore, healthcare providers are increasingly focusing on training and resources to better manage patients at risk of developing gangrene. As educational initiatives expand, the demand for effective treatment options and preventive measures within the gangrene market may also rise, contributing to overall market growth. ### Rising Incidence of Chronic Conditions The increasing prevalence of chronic conditions such as diabetes, obesity, and cardiovascular diseases in the US is a critical driver for the gangrene market. These conditions are closely linked to the development of gangrene, as they can impair blood circulation and lead to tissue damage. Recent data indicates that nearly 34 million Americans have diabetes, a figure that is expected to rise, thereby increasing the risk of gangrene. This trend suggests that as the population grapples with these chronic diseases, the demand for effective gangrene treatments will likely escalate. Consequently, the gangrene market may experience growth as healthcare systems adapt to address the needs of this vulnerable population. ### Technological Innovations in Wound Care Technological advancements in wound care are transforming the landscape of the gangrene market. Innovations such as bioengineered skin substitutes, advanced dressings, and telemedicine solutions are becoming increasingly prevalent. These technologies not only improve healing rates but also enhance patient monitoring and management. For instance, the introduction of smart dressings that can detect infection and provide real-time data to healthcare providers may significantly reduce complications associated with gangrene. The market for advanced wound care products is expected to grow at a CAGR of 6.5% through 2027, indicating a robust demand for innovative solutions in the gangrene market. This trend suggests that ongoing research and development will continue to play a crucial role in shaping the future of gangrene treatment. ## Future Outlook The [Gangrene Market](https://www.marketresearchfuture.com/reports/gangrene-market-1875) is projected to grow at a 5.8% CAGR from 2025 to 2035, driven by advancements in treatment technologies and increasing awareness of wound care. **New opportunities:** - Development of telemedicine platforms for remote consultations - Investment in advanced wound care products and technologies - Expansion of partnerships with healthcare providers for integrated care solutions By 2035, the gangrene market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Wet Gangrene (Largest) vs. Dry Gangrene (Fastest-Growing) In the US gangrene market, the distribution of market share among the types reveals that Wet Gangrene holds the most significant portion, indicating a higher prevalence of cases and thus greater clinical attention. Dry Gangrene follows as a notable segment, with the remainder spread across Gas Gangrene and others, reflecting a more specialized nature of these conditions. This distribution underscores the varying degrees of urgency and treatment approaches for each type, with Wet Gangrene necessitating immediate intervention. Growth trends within the segment are influenced by a combination of factors such as rising awareness about gangrene types, advances in treatment methodologies, and increasing incidences related to chronic diseases. Specifically, the diabetic population is a key driver for growth in Dry Gangrene due to its susceptibility to skin conditions and infections. Additionally, improvements in healthcare infrastructure and patient education are expected to bolster treatment rates and recovery outcomes, contributing to the overall expansion of the segment. Wet Gangrene (Dominant) vs. Dry Gangrene (Emerging) Wet Gangrene is characterized by the rapid spread of infection and inflammation, often leading to tissue necrosis due to bacterial invasion, making it the dominant type in clinical settings. It typically requires immediate medical intervention, thereby reflecting its substantial market share as healthcare professionals aim to address acute cases swiftly. On the other hand, Dry Gangrene, while less prevalent, is gaining recognition as an emerging segment primarily affecting individuals with underlying vascular or neuropathic conditions. Its growth is attributed to the increasing incidence of diabetes and other circulatory system disorders, prompting healthcare providers to focus on preventive measures and management strategies to mitigate risks associated with gangrene. ### By Treatment: Hyperbaric Oxygen Chamber (Largest) vs. Amputation (Fastest-Growing) In the US gangrene market, the treatment segment showcases distinct distribution among various methods. The Hyperbaric Oxygen Chamber stands as the largest contributor, attributed to its increasing recognition for treating chronic wounds and enhancing tissue oxygenation. Amputation, while smaller in comparison, has been gaining momentum due to its necessity in advanced gangrene cases, prompting a reevaluation of treatment strategies among professionals. The 'Others' category covers alternative treatments that, although they play a role, do not currently dominate the treatment landscape. Growth trends indicate a shifting paradigm towards more efficient treatment options in the gangrene segment. The rising prevalence of chronic wounds and diabetic ulcers fuels interest in Hyperbaric Oxygen Chambers, emphasizing their therapeutic benefits. Amputation, noted for its accelerated growth, is increasingly viewed as an unavoidable option in critical cases where necrotic tissue threatens survival. Collectively, these trends reflect a market attentive to both immediate clinical needs and long-term recovery outcomes. Hyperbaric Oxygen Chamber (Dominant) vs. Amputation (Emerging) The Hyperbaric Oxygen Chamber serves as a dominant treatment method within the gangrene segment, primarily due to its efficacy in promoting wound healing and tissue regeneration. This treatment utilizes high-pressure oxygen to enhance oxygen delivery to affected tissues, improving healing rates significantly. On the other hand, Amputation is viewed as an emerging necessity in severe gangrene cases. As a definitive intervention, it addresses advanced necrosis and prevents further complications. While Hyperbaric Chamber therapy is recognized for its non-invasive approach, the urgency and immediacy of amputation make it essential when dealing with critically affected limbs. Both options reflect the diversity of treatment strategies in the market, catering to varying patient needs and clinical scenarios. ### By End-User: Hospital (Largest) vs. Clinic (Fastest-Growing) In the US gangrene market, the hospital segment leads with a significant share, accommodating a large volume of patients with severe infections requiring advanced medical interventions. Hospitals are equipped with specialized facilities and personnel to handle complex cases of gangrene, contributing to their dominant position in the market. On the other hand, the clinic segment, while smaller, is rapidly expanding due to the increasing focus on outpatient care and early treatment options, enhancing accessibility for patients. Growth trends in this segment are driven by several factors. The rising incidence of diabetic foot ulcers and peripheral vascular diseases has led to an increased demand for gangrene treatment within both hospitals and clinics. Furthermore, heightened awareness regarding the early detection of gangrene and advancements in wound care management in clinics are attracting more patients, thereby supporting the segment's growth. Rehabilitation centers also play a crucial role by providing post-treatment care and education to prevent recurrence, but their market impact remains less pronounced compared to hospitals and clinics. Hospital (Dominant) vs. Clinic (Emerging) The hospital segment is characterized by its comprehensive service offerings, including surgical interventions, specialized care units, and multidisciplinary treatment teams that manage complex cases of gangrene effectively. Hospitals are essential in providing immediate care for severe infections and have the infrastructure to support varied and intensive treatment options. In contrast, clinics are emerging as an accessible alternative for early-stage treatment, enabling patients to receive timely care without the need for hospitalization. The growing trend towards outpatient services and preventive care is propelling clinics' market presence, positioning them as vital players in managing gangrene and related conditions, particularly in facilitating early intervention and ongoing patient education. ## Competitive Benchmarking The gangrene market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Smith & Nephew (GB), Acelity L.P. Inc. (US), and Organogenesis Inc. (US) are actively shaping the market dynamics. Smith & Nephew (GB) focuses on advanced wound management solutions, leveraging its expertise in regenerative medicine to enhance treatment outcomes. Acelity L.P. Inc. (US) emphasizes its commitment to innovation through the development of novel therapies, while Organogenesis Inc. (US) is strategically positioned in the market with its focus on cellular and tissue-based products, catering to the growing demand for effective gangrene treatments. Collectively, these strategies foster a competitive environment that prioritizes patient-centric solutions and technological advancements.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for diverse product offerings and fosters competition, compelling companies to innovate continuously. The collective influence of these key players drives the market towards more effective and accessible treatment options for gangrene. In October Smith & Nephew (GB) announced a strategic partnership with a leading technology firm to integrate AI-driven analytics into its wound management solutions. This move is likely to enhance patient outcomes by providing real-time data analysis, enabling healthcare providers to make informed decisions swiftly. The integration of AI signifies a shift towards more personalized treatment approaches, potentially setting a new standard in the industry. In September Acelity L.P. Inc. (US) launched a new product line aimed at improving the healing process for chronic wounds associated with gangrene. This product line, which incorporates advanced biomaterials, is expected to address unmet needs in the market. The introduction of such innovative solutions may strengthen Acelity's market position and appeal to healthcare providers seeking effective treatment options. In August Organogenesis Inc. (US) expanded its distribution network across the US, enhancing its ability to deliver its cellular and tissue-based products to a broader patient population. This strategic move not only increases accessibility but also positions Organogenesis to capture a larger market share. The expansion reflects a growing recognition of the importance of timely access to advanced treatment options in managing gangrene. As of November current competitive trends in the gangrene market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Companies that prioritize innovation and adaptability are likely to thrive in this evolving market, as they respond to the growing demand for effective and efficient gangrene treatments. ## Recent News & Developments Recent developments in the US Gangrene Market have highlighted significant advancements in treatment options and research initiatives. Companies such as Merck and Co., Bristol Myers Squibb, and Gilead Sciences have been focusing on new therapeutic compounds targeting gangrene-related conditions. In terms of mergers and acquisitions, notable activity includes Novartis acquiring a promising biotechnology firm in September 2023, which is expected to enhance its portfolio in the treatment of chronic wounds associated with gangrene. Additionally, Pfizer has expanded its research partnerships to explore innovative therapies that reduce gangrene incidence. Market valuation has seen growth due to increasing investments in biotechnology and novel drug development, with Eli Lilly and Company and Amgen reporting substantial quarterly earnings attributed to their advancements in wound care therapies. Over the last few years, there has been a heightened emphasis on antibiotic resistance, with Roche and Sanofi launching collaborative efforts aimed at overcoming resistant infections related to gangrene in April 2022. These activities have collectively contributed to an evolving landscape in the US Gangrene Market, bolstered by increasing healthcare expenditures and a focus on advanced treatment methodologies. ## Report Scope | MARKET SIZE 2024 | 0.318(USD Million) | | --- | --- | | MARKET SIZE 2025 | 0.337(USD Million) | | MARKET SIZE 2035 | 0.592(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Smith & Nephew (GB), MediWound Ltd. (IL), Acelity L.P. Inc. (US), Organogenesis Inc. (US), Mölnlycke Health Care AB (SE), ConvaTec Group PLC (GB), B. Braun Melsungen AG (DE), 3M Company (US) | | Segments Covered | Type, Treatment, End-User | | Key Market Opportunities | Advancements in wound care technologies enhance treatment options in the gangrene market. | | Key Market Dynamics | Rising prevalence of diabetes and vascular diseases drives demand for advanced gangrene treatment options in the US. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US gangrene market in 2024?** A: The overall market valuation was $0.318 Million in 2024. **Q: What is the projected market size for the US gangrene market by 2035?** A: The projected valuation for 2035 is $0.592 Million. **Q: What is the expected CAGR for the US gangrene market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 5.8%. **Q: Which companies are the key players in the US gangrene market?** A: Key players include Smith & Nephew, MediWound Ltd., Acelity L.P. Inc., and others. **Q: How does the market segment for Dry Gangrene perform in terms of valuation?** A: The valuation for Dry Gangrene ranges from $0.095 Million to $0.175 Million. **Q: What is the valuation range for Wet Gangrene in the US gangrene market?** A: The valuation for Wet Gangrene is between $0.115 Million and $0.205 Million. **Q: What treatment options are available in the US gangrene market?** A: Treatment options include Hyperbaric Oxygen Chamber and Amputation, with valuations of $0.127 Million to $0.227 Million and $0.095 Million to $0.175 Million, respectively. **Q: What is the market performance for Gas Gangrene?** A: The valuation for Gas Gangrene ranges from $0.065 Million to $0.115 Million. **Q: Which end-users are significant in the US gangrene market?** A: Significant end-users include hospitals and clinics, with valuations of $0.127 Million to $0.227 Million and $0.095 Million to $0.165 Million, respectively. **Q: What is the valuation for rehabilitation centers in the US gangrene market?** A: The valuation for rehabilitation centers is between $0.063 Million and $0.11 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gangrene-market-19941*